Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H40O3 |
| Molecular Weight | 412.6047 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2OC(=O)CCC5CCCCC5
InChI
InChIKey=TXLCJMHILCSZJG-QNTYDACNSA-N
InChI=1S/C27H40O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h17-18,21-25H,2-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.genome.jp/dbget-bin/www_bget?dr:D01476 and http://mymuscleworld.com/sanabolicum-profile/
Curator's Comment: Description was created based on several sources, including
http://www.genome.jp/dbget-bin/www_bget?dr:D01476 and http://mymuscleworld.com/sanabolicum-profile/
Nandrolone cyclohexylpropionate (a derivative of Nandrolone, which is approved by FDA) is an anabolic steroid. Nandrolone cyclohexylpropionate is reported as an ingredient of Sanabolicum in Austria. Sanabolicum is a rarely found version of the anabolic androgenic steroid nandrolone, with a CycloHexylPropionate ester. This modification makes nandrolone more anabolic (muscle building) and less androgenic. Nandrolone cyclohexylpropionate is an androgen receptor agonist.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1871 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Sanabolicum Approved UseSanabolicum can have a positive effect and provide benefits for all the following:
Burn Victims
HIV & AIDS Treatment
Most Muscle Wasting Diseases
Geriatric Weakness
Anemia
Ulcers
Adolescent Dwarfism
Osteoporosis
Anti-Aging |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30.9 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9103484/ |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.14 ng/mL |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
4.26 ng/mL |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.16 ng/mL |
150 mg single, intramuscular dose: 150 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
155 nM × day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9103484/ |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
400 ng × h/mL |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
862 ng × h/mL |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1261 ng × h/mL |
150 mg single, intramuscular dose: 150 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.25 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9103484/ |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.1 day |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
11.7 day |
100 mg single, intramuscular dose: 100 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
11.8 day |
150 mg single, intramuscular dose: 150 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
NANDROLONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2360
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
213-013-3
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
100000089015
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
Nandrolone cyclohexylpropionate
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
C95976
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
912-57-2
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
SUB23549
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
101905
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
K4NE48GG1Y
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104906
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY | |||
|
DTXSID3057852
Created by
admin on Mon Mar 31 19:24:19 GMT 2025 , Edited by admin on Mon Mar 31 19:24:19 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
